Brentuximab vedotin is a drug approved for treating anaplastic large cell lymphoma and some patients with Hodgkin lymphoma. It has two parts: one (an antibody) that attaches to a protein on the surface of cancer cells called CD30, and another (an anticancer drug called monomethyl auristatin E) that kills the cancer. Clinical studies have indicated that it may also be effective for treating some people with cutaneous T-cell lymphoma (CTCL).
The purpose of this study is to compare the effectiveness of brentuximab vedotin with standard therapy (methotrexate or bexarotene) in patients with CD30-positive CTCL that persists despite previous treatment. Patients will be randomly assigned to receive brentuximab vedotin, methotrexate, or bexarotene.